AI-aided colonoscopy improves ADR

AI may be more accurate vs. traditional methods at classifying patients into prostate cancer risk groups

For localized prostate cancer, multimodal artificial intelligence models have revealed a more accurate way to assess prostate cancer risk. By combining advanced artificial intelligence with digital pathology images and clinical data, researchers developed a way to approach risk classification that outperforms traditional methods. These findings were published in JCO Precision Oncology. The research found that...

November 08, 2024

Vol.50 No.42

Clinical Roundup

Neuro-oncology experts release clinical practice guidelines for using AI in brain cancer diagnosis, monitoring, treatment

An international, multidisciplinary team of leading neuro-oncology researchers and clinicians has released new recommendations for good clinical practice—a set of guidelines that helps ensure clinical trial results are reliable, and patients are protected—regarding the use of artificial intelligence methods to more accurately diagnose, monitor, and treat brain cancer patients. The team recently published two companion...

November 08, 2024

Vol.50 No.42

In Brief

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

OmniaBio Inc. announced the opening of a new North American cell and gene therapy manufacturing and artificial intelligence center of excellence, which is now Canada’s largest contract development and manufacturing organization facility dedicated to CGT.

October 25, 2024

Vol.50 No.40

Clinical Roundup

East Alabama Medical Center, Inflo Health, ACR ImPower program collaboration boosts recommendations follow-up by 74%

Inflo Health, a leader in AI-driven radiology follow-up care orchestration, announced that it has qualified for the American College of Radiology’s Learning Network Vendor Partner designation on the heels of a successful collaboration that saw East Alabama Medical Center significantly improve recommendations follow-up rates.

October 25, 2024

Vol.50 No.40

In Brief

David Baker, Demis Hassabis, and John Jumper receive 2024 Nobel Prize in Chemistry

David BakerPhoto credit: Niklas Elmehed © Nobel Prize OutreachDemis HassabisPhoto credit: Niklas Elmehed © Nobel Prize OutreachJohn M. JumperPhoto credit: Niklas Elmehed © Nobel Prize OutreachDavid Baker, Demis Hassabis, and John M. Jumper received the 2024 Nobel Prize in Chemistry for their work in protein design and prediction.

October 11, 2024

Vol.50 No.38

In Brief

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Four NCI-designated cancer centers—Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins—have joined together and secured funding from AWS, Deloitte, Microsoft, and NVIDIA, to create the Cancer AI Alliance.

October 04, 2024

Vol.50 No.37

AI-aided colonoscopy improves ADR

YOU MAY BE INTERESTED IN

AI may be more accurate vs. traditional methods at classifying patients into prostate cancer risk groups

Neuro-oncology experts release clinical practice guidelines for using AI in brain cancer diagnosis, monitoring, treatment

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

East Alabama Medical Center, Inflo Health, ACR ImPower program collaboration boosts recommendations follow-up by 74%

David Baker, Demis Hassabis, and John Jumper receive 2024 Nobel Prize in Chemistry

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Renew today!

Subscriber content

Login